Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between...

The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed significantly over the last decade with the introduction of combination strategies. However, recent real-world evidence on their use in practice is limited, especially in Europe and Asia.

This cross-sectional study included men with mHSPC receiving first-line therapy in EU4, the UK, Japan and China between January 1, 2020, and December 31, 2024. The IQVIA Oncology Dynamics database was used to derive patient-level data on physician-reported initial treatment for mHSPC.

Of 23,101 men included, 15,275, 4,875, and 2,951 in EU4, the UK, and Asia, received treatment for mHSPC. Use of androgen deprivation therapy (ADT) monotherapy ranged from 29-44% in EU4/UK and 50-59% in Asia. ADT plus androgen receptor inhibitor (ARPI) was used in 47% of patients in EU4, 54% in the UK, and 35-38% in Asia. From 2020-2024, ADT monotherapy decreased from 60% to 24% in EU4, 54% to 23% in the UK, and 83% to 39% in Asia, with corresponding increases in ADT plus ARPI use. ADT plus ARPI plus docetaxel use increased throughout the study, becoming more prominent from 2023 in EU4/UK; usage went from 0.1% in 2020 to 10% in 2024. Uptake was slower in Asia. Compared with recurrent mHSPC, a high proportion received combination therapy for de novo mHSPC.

Findings highlight the adoption of combination strategies with either doublet or docetaxel triplet regimens between 2020 and 2024. One-fourth of patients received ADT monotherapy in 2024.